Trade IPHA stock anytime, 24x5 in Singapore
Regulated by
Monetary Authority of Singapore (MAS)
Trusted by
400,000+ users
Innate Pharma S.A. ADS (IPHA) is trading at US$1.90, down 0.52% today as of Sep 18, 16:00 EDT. The company has a market capitalisation of US$252.44M. Over the past 52 weeks, IPHA has traded between US$1.17 and US$2.71. On Syfe you can trade IPHA with $0 commission and add it to your watchlist.
| Previous close | US$1.91 |
|---|---|
| Market cap | US$252.44M |
| 52-week range | US$1.17 – US$2.71 |
| Volume | 91.44K |
| Exchange | US |
Add to Watchlist
Set Price Alert
Innate Pharma S.A. ADS
Innate Pharma SA is a global, clinical-stage biotechnology company, which engages in developing immunotherapies for cancer patients. Its product pipeline includes Lacutamab, Monalizumab, Avdoralimab, and IPH62. The company was founded by Hervé Eloi Dominique Brailly, Eric Vivier, Marc Bonneville, Alessandro Moretta, Jean-Jacques Fournié, and François Romagné on September 23, 1999 and is headquartered in Marseille, France.
Year: 2015
Leerink Partners Upgrades Innate Pharma to Outperform From Market Perform, Adjusts PT to $4 From $3
Aug 11, 11:50 AM · MT Newswires
Innate Pharma, Sobi Partner on Late-Stage Study for Lacutamab
Aug 10, 8:09 AM · MT Newswires
Innate Pharma, Swedish Orphan Biovitrum Partner to Advance Phase 3 Lymphoma Drug; Shares Surge Pre-Bell
Aug 10, 7:36 AM · MT Newswires
Innate Pharma Closes Enrollment in Phase 1 Advanced Solid Tumors Study
Jul 21, 8:10 AM · MT Newswires
Innate Pharma S.A. ADS (IPHA) stock is trading at US$1.90, -0.52% from the previous close of US$1.91.
The market cap for Innate Pharma S.A. ADS (IPHA) stock is approximately US$252.44M.
The 52-week high for Innate Pharma S.A. ADS (IPHA) stock is US$2.71.
The 52-week low for Innate Pharma S.A. ADS (IPHA) stock is US$1.17.
Innate Pharma S.A. ADS (IPHA) does not currently pay a dividend.
Stay on top of IPHA
Price moves, news and earnings — straight to your inbox.
Est. order value
US$0.00
Snapshot
Popular Stocks in Singapore
